title: Venous Thromboembolism After Knee Arthroscopy in Undiagnosed Familial Thrombophilia.
abstract: Venous thromboembolism is uncommon after knee arthroscopy, and there are no guidelines for thromboprophylaxis in elective routine knee arthroscopy. Preoperative evaluation of common thrombophilias should provide guidance for postarthroscopy thromboprophylaxis in otherwise healthy patients who are at high risk for venous thromboembolism. This study assessed 10 patients with venous thromboembolism after total hip or knee arthroplasty. Patients were assessed if venous thromboembolism occurred within 6 months after knee arthroscopy (n=10) or total hip or knee arthroplasty (n=21). This study assessed gene mutations (factor V Leiden, prothrombin G20210A, plasminogen activator inhibitor, methylenetetrahydrofolate reductase) and serologic thrombophilias (high levels of factors VIII and XI, homocysteine, anticardiolipin immunoglobulin G and immunoglobulin M antibodies, and lupus anticoagulant; low antigenic protein C, S, and free S; and antithrombin III deficiency). The same coagulation data were obtained for normal subjects (n=110). The major thrombophilias in the arthroscopy group were factor V Leiden heterozygosity (40%), high factor VIII level (50%), and high homocysteine (30%). The respective values in control subjects were 2% (P=.0004), 7% (P=.0011), and 5% (P=.02). When the arthroscopy group was compared with the 21 patients who had venous thromboembolism after total hip or knee arthroplasty, the sole difference was factor V Leiden heterozygosity, which was 40% vs 0%, respectively (P=.007). Although venous thromboembolism after knee arthroscopy is uncommon, to identify high-risk patients and guide postoperative thromboprophylaxis, the authors suggest routine preoperative measurement of 3 common familial thrombophilias: factor V Leiden, factor VIII, and homocysteine. [Orthopedics. 2016; 39(6):e1052-e1057.].
authors.forename: Vybhav
authors.initials: V
authors.lastname: Jetty
authors.forename: Charles J
authors.initials: CJ
authors.lastname: Glueck
authors.forename: Richard A
authors.initials: RA
authors.lastname: Freiberg
authors.forename: Ping
authors.initials: P
authors.lastname: Wang
mesh_terms: D017153:Antibodies, Anticardiolipin / Q000097:blood; D020152:Antithrombin III Deficiency / Q000097:blood / Q000150:complications; D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects; D019645:Arthroplasty, Replacement, Knee / Q000009:adverse effects; D001182:Arthroscopy / Q000009:adverse effects*; D019774:Blood Coagulation Factor Inhibitors / Q000097:blood*; D001779:Blood Coagulation Factors / Q000235:genetics* / Q000378:metabolism*; D005165:Factor V / Q000235:genetics; D005169:Factor VIII / Q000378:metabolism; D005172:Factor XI / Q000378:metabolism; D005260:Female; D006710:Homocysteine / Q000097:blood; D006801:Humans; D007719:Knee Joint / Q000601:surgery; D008297:Male; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics; D009154:Mutation; D017395:Plasminogen Activator Inhibitor 1 / Q000235:genetics; D011516:Prothrombin / Q000235:genetics; D019851:Thrombophilia / Q000150:complications* / Q000175:diagnosis / Q000235:genetics; D054556:Venous Thromboembolism / Q000209:etiology*
chemical_list: D017153:Antibodies, Anticardiolipin; D019774:Blood Coagulation Factor Inhibitors; D001779:Blood Coagulation Factors; D017395:Plasminogen Activator Inhibitor 1; C095381:factor V Leiden; D006710:Homocysteine; D005165:Factor V; D011516:Prothrombin; D005169:Factor VIII; D005172:Factor XI; D042965:Methylenetetrahydrofolate Reductase (NADPH2)